Revenue growth outlook for FY27 and split between ARPOB and volume/occupancy growth

Rajesh Sharma gave full-year guidance: revenue ₹2,080 Cr (+24%), EBITDA ₹530 Cr (+25%), PAT ₹360 Cr (+32%). Sudesh Sharma added ARPOB guidance of 10-12% and a blended EBITDA margin framework of 26.7-27%, with mature hospitals above 60% occupancy at 30-31% EBITDA and sub-60% hospitals at 15-20%.

Strategy to ramp up new acquisitions Rudrapur and Zirakpur

Dr. Sanjay Sharma detailed: Rudrapur will be scaled to 330 beds, with all super-specialties, targeting ₹100 Cr revenue in first year and ₹140 Cr in second year, EBITDA ₹20-22 Cr first year. Zirakpur will leverage the Tricity cluster, targeting ₹70-75 Cr revenue in FY28 at 25-26% EBITDA margin. Management highlighted that both will follow the affordable care model with similar payer mix.

Timeline and mechanism for promoter stake dilution to meet 75% listing requirement

Sudesh Sharma said: "Too early to comment on that. ... I cannot specify exact timeline right now." Noted the three-year window ends December 2028 and that a clear deployment opportunity (acquisition) would trigger equity raising.

Quantification of CGHS rate hike benefit flowing into EBITDA from Q2 onwards

Dr. Sanjay Sharma stated the full ARPOB impact is 7-7.5%, but the additional benefit will be largely utilised for high-end equipment and capex, so the direct impact on PAT/EBITDA is not major, although overall EBITDA margin of 26-27% and PAT margin of 17-18% will be maintained.

Park Medi World Q1 FY27 Earnings Call — Analysis (NSE: PARKHOSPS)

Park Medi World reported steady Q1 FY27 with revenue ₹476 Cr (+19% YoY) and PAT ₹89 Cr (+35%), while unveiling aggressive bed expansion plans to reach 5,740 beds by FY28.

8 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Operating EBITDA (excl. other income) ₹126 Cr ( +20% YoY ) . New guidance — FY27 full-year fy27 blended ebitda m… 26.7%-27% . New story: Relentless capacity expansion through acquisiti… .

Results

Revenue ₹476 Cr (+19% YoY); EBITDA (excl. other income) ₹126 Cr, margin 26.5% (+20 bps YoY); PAT ₹89 Cr (+35% YoY), PAT margin 18.6% (+220 bps YoY).

Financial highlights

Park Medi World Q1 FY27 reported figures
Metric	Value	Change	Basis
Revenue from operations	₹476 Cr	+19%	yoy · Q1FY27
Operating EBITDA (excl. other income)	₹126 Cr	+20%	yoy · Q1FY27
EBITDA margin (excl. other income)	26.5%	+20 bps	yoy · Q1FY27
PAT	₹89 Cr	+35%	yoy · Q1FY27
PAT margin	18.6%	+220 bps	yoy · Q1FY27
ARPOB	₹30,444	+12%	yoy · Q1FY27
IPD volume	26,304 patients	+16%	yoy · Q1FY27
OPD volume	2,23,446 patients	+17%	yoy · Q1FY27
Network occupancy	56%	−12 pp	yoy · Q1FY27
High-end specialty revenue share	62%	+440 bps	yoy · Q1FY27 · of total revenue
Bed capacity	3,960 beds	+32%	point_in_time · Q1FY27 · as of 30 Jun 2026
Term debt (excl. lease liability)	₹25.6 Cr		point_in_time · Q1FY27 · as of 30 Jun 2026
Net worth	₹2,100 Cr		point_in_time · Q1FY27 · as of 30 Jun 2026
Fixed deposits	₹300 Cr		point_in_time · Q1FY27 · as of 30 Jun 2026
Government insurance scheme payer mix	77%		point_in_time · Q1FY27 · of total revenue

Guidance

Management guided FY27 revenue of ₹2,080 Cr (+24% YoY), EBITDA of ₹530 Cr (+25% YoY), and PAT of ₹360 Cr (+32% YoY).

What management committed to

We expect to end financial year 2027 with 4,740 beds. — 4,740 beds, FY27
We will be at 5,740 beds capacity by FY’28. — 5,740 beds, FY28
For FY’27 we are expecting a top line of Rs.2,080 crores, EBITDA of Rs.530 crores, and PAT of Rs.360 crores. — ₹2,080 Cr revenue, ₹530 Cr EBITDA, ₹360 Cr PAT, FY27
ARPOB guidance for FY’27 is in a 10-12% band, and this trend will continue for the next two years. — 10-12%, FY’27 and FY28
Blended EBITDA margin of 26.7%-27% will hold for complete financial year FY27. — 26.7%-27%, FY27
[Rudrapur facility] in the first year [of operations] will generate Rs.100 crores of revenue, EBITDA of Rs.20-22 crores, and PAT of Rs.12-13 crores. — ₹100 Cr revenue, EBITDA ₹20-22 Cr, PAT ₹12-13 Cr, first year of operations
[Zirakpur facility] in FY28 should generate revenue of Rs.70-75 crores with an EBITDA of about 25-26%. — ₹70-75 Cr revenue, 25-26% EBITDA margin, FY28
The blended CAPEX per bed for new facilities added in FY27 and FY28 will remain at Rs.36 lakhs per bed. — ₹36 lakhs per bed, FY28
We remain fully funded for our stated growth plan to reach 5,740-beds by March 2028 through internal accruals and IPO proceeds, with recourse to any material fresh debt. — no material fresh debt, FY28
We expect that there will be an increase of 150-200 basis points in RoCE over the next 12-18 months. — 150-200 bps increase, next 12-18 months
Our payer mix will gradually shift to a 70:30 split between government insurance schemes and self-pay/private insurance/TPA in the next 12-18 months. — 70:30, next 12-18 months
We expect debtor days to trend towards our medium-term target of 125-days to 130-days. — 125-130 days, medium-term

Key themes

Aggressive capacity expansion and cluster densification

How the narrative shifted

Relentless capacity expansion through acquisitions & greenfield: bullish

Operational commentary

Acquired The Medicity Hospital, Rudrapur (330 beds, ₹177 Cr) – commissioned 2 Aug 2026, first year revenue target ₹100 Cr, EBITDA ₹20-22 Cr.
Definitive agreement to acquire Mehar Hospital, Zirakpur (150 beds, ₹107 Cr) – commissioning Nov-Dec 2026, FY28 revenue target ₹70-75 Cr, EBITDA margin 25-26%.
100-bed extension at Palam Vihar, Gurgaon ('Park Platinum') to be commissioned Nov-Dec 2026, taking consolidated Gurgaon capacity to 750 beds.
Narela 200-bed hospital (acquired via insolvency) on track for commissioning.
Total bed capacity expected to reach 4,740 by end FY27 and 5,740 by FY28; 1,490 beds added in CY2026 (+46% vs CY2025).
Agra (360 beds, commissioned Feb 2026) and Panchkula (350 beds, commissioned Apr 2026) ramping up in line with expectations.
CGHS rate revision (12-15% hike in Oct 2025) partially flowing through; full impact of ~7-7.5% on ARPOB expected from Q2 FY27, largely reinvested in capex/equipment upgrade.
Case mix shift to high-end tertiary/quaternary care: specialty contribution up 440 bps YoY to 62%, driven by transplant, interventional cardiology, robot-assisted joint replacement programs.
Nine NABL-accredited labs, four more hospitals to obtain NABL accreditation in FY27.
Doctor retention strategy: full-time employment model, no visiting consultants, performance bonuses, ESOP; very low consultant attrition.

Analyst Q&A

Q. Revenue growth outlook for FY27 and split between ARPOB and volume/occupancy growth
Rajesh Sharma gave full-year guidance: revenue ₹2,080 Cr (+24%), EBITDA ₹530 Cr (+25%), PAT ₹360 Cr (+32%). Sudesh Sharma added ARPOB guidance of 10-12% and a blended EBITDA margin framework of 26.7-27%, with mature hospitals above 60% occupancy at 30-31% EBITDA and sub-60% hospitals at 15-20%.
Q. Strategy to ramp up new acquisitions Rudrapur and Zirakpur
Dr. Sanjay Sharma detailed: Rudrapur will be scaled to 330 beds, with all super-specialties, targeting ₹100 Cr revenue in first year and ₹140 Cr in second year, EBITDA ₹20-22 Cr first year. Zirakpur will leverage the Tricity cluster, targeting ₹70-75 Cr revenue in FY28 at 25-26% EBITDA margin. Management highlighted that both will follow the affordable care model with similar payer mix.
Q. Timeline and mechanism for promoter stake dilution to meet 75% listing requirement
Sudesh Sharma said: "Too early to comment on that. ... I cannot specify exact timeline right now." Noted the three-year window ends December 2028 and that a clear deployment opportunity (acquisition) would trigger equity raising.
Q. Quantification of CGHS rate hike benefit flowing into EBITDA from Q2 onwards
Dr. Sanjay Sharma stated the full ARPOB impact is 7-7.5%, but the additional benefit will be largely utilised for high-end equipment and capex, so the direct impact on PAT/EBITDA is not major, although overall EBITDA margin of 26-27% and PAT margin of 17-18% will be maintained.

View source

Research and educational content only. Not investment advice.